A High Throughput Phenotypic Screening reveals compounds that counteract premature osteogenic differentiation of HGPS...

Area of Science:

• Genetics
• Cell Biology
• Pharmacology

Background:

• Hutchinson-Gilford progeria syndrome (HGPS) is a rare, fatal genetic disorder causing accelerated aging in children.
• Induced pluripotent stem cells (iPSCs) from HGPS patients offer a model for studying disease mechanisms and testing therapies.
• Developing effective pharmacological treatments for HGPS is a critical unmet need.

Purpose of the Study:

• To identify small molecules that can correct cellular defects in HGPS using an iPSC-based model.
• To screen a large library of compounds for their ability to normalize osteogenic differentiation in HGPS mesenchymal stem cells (MSCs).
• To find therapeutic agents that reduce progerin expression, a key hallmark of HGPS.

Main Methods:

• Utilized high-throughput screening of 2800 small molecules.
• Employed HGPS iPSC-derived MSCs undergoing osteogenic differentiation.
• Assessed alkaline phosphatase activity as a marker of osteogenic differentiation.
• Quantified progerin expression in response to promising compounds.

Main Results:

• Seven compounds were identified that normalized the osteogenic differentiation process in HGPS MSCs.
• All-trans retinoic acid and 13-cis-retinoic acid were among the identified compounds.
• These two retinoic acids also demonstrated a reduction in progerin expression.

Conclusions:

• High-throughput drug screening using HGPS iPSC-derived cells is a viable strategy for identifying therapeutic compounds.
• Retinoic acid derivatives show promise as potential therapeutic agents for HGPS.
• This approach may also be applicable to finding treatments for other aging-related disorders.